Jeanette M. Bjorkquist - 17 Jun 2026 Form 4 Insider Report for ASSEMBLY BIOSCIENCES, INC. (ASMB)

Reporting relationship: PFO and PAO
Issuer ticker: ASMB
Reported as of: 17 Jun 2026
Net transaction value: -$674
SEC form: 4
Accepted by SEC: 18 Jun 2026, 16:05:04 UTC
Prior SEC filing: 05 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ John O. Gunderson, as Attorney-in-Fact

Key filing fact

Jeanette M. Bjorkquist filed Form 4 for ASSEMBLY BIOSCIENCES, INC. (ASMB) on 18 Jun 2026.

Key facts

This page summarizes Jeanette M. Bjorkquist's Form 4 filing for ASSEMBLY BIOSCIENCES, INC. (ASMB).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Jun 2026, 16:05.

Change

Previous filing in this sequence was filed on 05 Jun 2026.
Current net transaction value: -$674.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001945064 Primary reporting owner

Bjorkquist Jeanette M

Relationship: PFO and PAO
Address: C/O ASSEMBLY BIOSCIENCES, INC., TWO TOWER PLACE, 7TH FLOOR, SOUTH SAN FRANCISCO
Signature: /s/ John O. Gunderson, as Attorney-in-Fact
Signature date: 18 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ASMB transaction

Common Stock

Sale

Transaction value: $674
Shares: -29
Change %: -0.2%
Price: $23.25
Shares after: 14,560
Date: 17 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.